close
hp-tabs-0 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home0.jpg, Fenwick Represents Dermira | in $1.1B Acquisition by Lilly Fenwick Represents Dermira | in $1.1B Acquisition by Lilly Fenwick is representing Dermira, a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions, in its pending acquisition by Lilly for approximately $1.1 billion. 1 https://www.fenwick.com/experience/Pages/Fenwick-Represents-Dermira-in-Pending-Acquisition-by-Lilly.aspx hp-tabs-1 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home2.jpg, Fenwick Insights Fenwick Insights INSIGHTS Fenwick’s latest survey compares the results of the 2019 proxy season in Silicon Valley with other large Bay Area public companies. 2 https://www.fenwick.com/Publications/Pages/2019-Proxy-Season-Results-in-Silicon-Valley-and-Large-Companies-Nationwide.aspx hp-tabs-2 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home1.jpg, TOP TIER Law360 has recognized Fenwick as a 2019 Powerhouse in recognition of our significant M&A and investment deals, major litigation wins and other successes. 3 https://www.fenwick.com/Media/Pages/Fenwick-Named-Law360-California-Powerhouse.aspx hp-tabs-3 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home4.jpg, Client Spotlight Client Spotlight CLIENT SPOTLIGHT Fenwick is guiding biotech company Audentes Therapeutics in its pending $3B acquisition by Astellas Pharma. 4 https://www.fenwick.com/experience/Pages/Fenwick-Represents-Audentes-Therapeutics-in-Pending-3-Billion-Acquisition-by-Astellas-Pharma.aspx hp-tabs-4 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home3.jpg, NEW YORK Crain's has named Fenwick one of the Best Places to Work in New York City for 2019. 5 https://www.fenwick.com/Media/Pages/Crains-Names-Fenwick-One-of-the-Best-Places-to-Work-in-New-York-City.aspx hp-tabs-0 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-1.jpg, Fenwick Represents Dermira | in $1.1B Acquisition by Lilly Fenwick Represents Dermira | in $1.1B Acquisition by Lilly Fenwick is representing Dermira, a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions, in its pending acquisition by Lilly for approximately $1.1 billion. https://www.fenwick.com/experience/Pages/Fenwick-Represents-Dermira-in-Pending-Acquisition-by-Lilly.aspx hp-tabs-1 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-2.jpg, Fenwick Insights Fenwick Insights INSIGHTS Fenwick’s latest survey compares the results of the 2019 proxy season in Silicon Valley with other large Bay Area public companies. https://www.fenwick.com/Publications/Pages/2019-Proxy-Season-Results-in-Silicon-Valley-and-Large-Companies-Nationwide.aspx hp-tabs-2 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-3.jpg, TOP TIER Law360 has recognized Fenwick as a 2019 Powerhouse in recognition of our significant M&A and investment deals, major litigation wins and other successes. https://www.fenwick.com/Media/Pages/Fenwick-Named-Law360-California-Powerhouse.aspx hp-tabs-3 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-4.jpg, Client Spotlight CLIENT SPOTLIGHT Fenwick is guiding biotech company Audentes Therapeutics in its pending $3B acquisition by Astellas Pharma. https://www.fenwick.com/experience/Pages/Fenwick-Represents-Audentes-Therapeutics-in-Pending-3-Billion-Acquisition-by-Astellas-Pharma.aspx hp-tabs-4 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-5.jpg, NEW YORK NEW YORK Crain's has named Fenwick one of the Best Places to Work in New York City for 2019. https://www.fenwick.com/Media/Pages/Crains-Names-Fenwick-One-of-the-Best-Places-to-Work-in-New-York-City.aspx